| Description | CQ211 is a potent and selective RIOK2 inhibitor with a Kd of 6.1 nM.CQ211 has shown potent proliferation inhibitory activity against various cancer cell lines in vitro. |
| In vivo | CQ211 (25 mg/kg; rat) inhibits the tumor progression with tumor growth inhibition (TGI) of 30.9%.[1] |
| Target activity | RIOK2:6.1 nM(Kd) |
| molecular weight | 521.49 |
| Molecular formula | C26H22F3N7O2 |
| CAS | 2648986-65-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 6.25 mg/mL (11.98 mM), Sonication is recommended. |
| References | 1. Ouyang Y, et al. Discovery of 8-(6-Methoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,5-dihydro-4H-[1,2,3]triazolo[4,5-c]quinolin-4-one (CQ211) as a Highly Potent and Selective RIOK2 Inhibitor. J Med Chem. 2022;65(11):7833-7842. |